Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vadadustat - Akebia Therapeutics

Next Previous
Drug Profile

Vadadustat - Akebia Therapeutics

Alternative Names: AKB-6548; MT 6548; PG 1016548; VAFSEO; Vafseo

Latest Information Update: 19 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Procter & Gamble
  • Developer Akebia Therapeutics; MEDICE; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical
  • Class Acetic acids; Amides; Antianaemics; Antivirals; Chlorobenzenes; Chlorophenols; Pyridines; Small molecules; Urologics
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia
  • Phase II Renal failure; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 07 Aug 2025 Akebia Therapeutics completes enrollment in phase III VOICE trial for Anaemia in the US (PO, Tablet) (NCT06520826)
  • 08 May 2025 Akebia Therapeutics receives a National Institute for Health and Care Excellence recommendation for Vadadustat for the treatment of Anemia
  • 08 May 2025 Vadadustat has boxed warning for increased risk of thrombotic vascular events, including major adverse cardiovascular events (MACE), increased risk of death and arterial and venous thrombotic events

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top